Interesting that the lenzilumab P3 trial criteria were changed today.
Severe trial was started about same time as ours. As of today about 60 more patients were added to the target number and the primary endpoint was changed from incidence of ventilation/death to time to recovery.
Not sure what it means to change a study so late in the process. They are excluding the most severe patients that we have accepted in our trial.
(I do have a small amount of my portfolio invested in HGEN, not anywhere close to what I have in CYDY)
Severe trial was started about same time as ours. As of today about 60 more patients were added to the target number and the primary endpoint was changed from incidence of ventilation/death to time to recovery.
Not sure what it means to change a study so late in the process. They are excluding the most severe patients that we have accepted in our trial.
(I do have a small amount of my portfolio invested in HGEN, not anywhere close to what I have in CYDY)